ORAI3 and breast cancer: To the best of our knowledge, this is the first report about the dysregulation of TRPC4 levels under pathological conditions, while an increase in Orai3 expression is responsible for the higher amplitude of SOCE in oestrogen receptor-positive breast cancer lines [24].